In January 2024, the Beijing Hemophilia Association Rare Disease Care Center and Shanghai RAAS Blood Products Co., Ltd., after negotiations, reached a deep cooperation agreement in the field of hemophilia charity and public welfare. They will work together to promote the development of charitable and public welfare activities related to hemophilia in China.

Shanghai RAAS Blood Products Co., Ltd. was established in 1988 and went public on the Shenzhen Stock Exchange in June 2008. It is a leading domestic blood products enterprise that integrates the collection of raw plasma, research and development, production, and sales of blood products. Their main products include human albumin, intravenous human immunoglobulin (PH4), human coagulation factor VIII, human fibrinogen, human prothrombin complex, human thrombin, and human fibrin sealant. Shanghai RAAS is one of the few domestic blood product manufacturers capable of extracting six components from plasma and has the most comprehensive range of coagulation factor products in the industry. The first virus-inactivated human coagulation factor VIII product in China was developed by Shanghai RAAS in 1995.

The Beijing Hemophilia Association Rare Disease Care Center was registered with the Beijing Civil Affairs Bureau in 2012, twice rated as a 5A-level social organization, and became a charity organization in 2017. The center's main activities include providing assistance to patients with rare diseases such as hemophilia and their families in education, medical care, psychological support, and employment. They also engage in knowledge dissemination and education activities related to rare diseases like hemophilia, organize consultations with medical experts, scholars, patients, and more in the field of rare diseases.

Over the years, the Hemophilia Association has been dedicated to its mission as a Chinese social organization and charity organization, adhering to the development core of "Chinese socialist charity." They have achieved some success in advocating and promoting policies related to hemophilia, conducting public welfare charity projects for hemophilia patients, disseminating disease knowledge, empowering patients, establishing a fully digital service platform, and promoting clinical treatment and drug research and development.

As a leading enterprise in the Chinese blood products industry, Shanghai RAAS has significant advantages in blood product research and development and production. They not only have a rational and comprehensive product layout but also continuously strive for innovation in the development of new drugs for the treatment of rare diseases such as hemophilia, providing safe and effective treatment guarantees for patients.

The Hemophilia Association and Shanghai RAAS share the common goal of further improving the current situation of patients with rare diseases such as hemophilia. They will leverage each other's strengths, explore various forms of social work, and promote the social integration of patients with rare diseases like hemophilia. This collaboration aims to contribute to the realization of the "Healthy China 2030" strategic goal.

Source:

https://mp.weixin.qq.com/s/ETpumeMocTpmHfuZriSFSg